NORTH WEST LUNG CENTRE

Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. About these numbers

• Turnover

  +5.2%

  £18,685,723 → £19,664,293

• Cash

  +52.1%

  £24,952,902 → £37,960,664

• Net assets

  +243.3%

  £38,492,515 → £132,146,362

• Employees

  +8%

  162 → 175

• Operating profit

  -26.4%

  £6,592,686 → £4,849,474

• Profit before tax

  +1,203.4%

  £7,291,227 → £95,035,009

• Wages

  +14.4%

  £6,700,399 → £7,664,220

Each % is (latest − prior) ÷ |prior| for the line item as filed. The comparison is only shown when the latest and prior accounts cover broadly equal-length periods — short or long stubs (typical around incorporation or a year-end change) are suppressed rather than misrepresented. Lines a company doesn't report are omitted. About these numbers

Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Margin ratios are hidden where reported turnover is too small relative to profit to yield a meaningful figure — typical of holding companies whose income is mostly subsidiary dividends rather than trading revenue. Sector-distribution context coming next.

Accounting basis

FRS 102

Reporting scope

Consolidated group

Auditor

Mitchell Charlesworth (Audit) Limited

Audit opinion

Unqualified (clean)

Going concern

Affirmed

“The trustees, having considered the proceeds from the sale of subsidiary shares post year end, are confident that the group has adequate resources to continue in operational existence for at least 12 months from the financial statements' approval date, and have prepared the financial statements on a going concern basis.”

Group structure

1. NORTH WEST LUNG CENTRE · parent
   1. Medicines Evaluation Unit Limited 84.92% · England & Wales · evaluating medicines for the pharmaceuticals industry
   2. CRO Solutions Limited 69.87% · England & Wales · clinical research organisation

Significant events

• “On 13th June 2025, North West Lung Centre disposed of its entire shareholdings in its subsidiary undertakings Medicines Evaluation Unit Limited and CRO Solutions Limited to IQVIA Limited.”

Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers

Filings

15

last 12 months

Capital events

0

last 24 months

Officers appointed

6

last 12 months

Officers resigned

2

last 12 months

Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.